ALK | Allergy solutions for life

Celebrating the past and future of allergy solutions for life

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy


  • Post date
    Six-month interim report (Q2) 2023
  • Post date
    Release date of six-month interim report (Q2) 2023 for ALK and audio cast
  • Post date
    President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor
  • Post date
    Three-month interim report (Q1) 2023
  • Post date
    Release date of three-month interim report (Q1) 2023 for ALK and audio cast
  • Post date
    ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
  • Post date
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    Annual General Meeting in ALK-Abelló A/S held on 23 March 2023
  • Post date
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
100 Years of Pioneering Allergy Solutions
A new book has been written about ALK’s fascinating development in the field of allergy
100 year history PDF
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.
A podcast
Investigator-initiated clinical trials in allergy immunotherapy
The call for applications is now open!
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.
The Henning Løwenstein Research Award 2024

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.